3-(5-Trifluoromethyl-3-pyridyl)-3,7-diazabicyclo[3.3.1]nonane | 345317-20-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(5-Trifluoromethyl-3-pyridyl)-3,7-diazabicyclo[3.3.1]nonane
• 英文别名: 3-(5-Trifluoromethyl-pyridin-3-yl)-3,7-diazabicyclo[3.3.1]nonane；3-[5-(Trifluoromethyl)pyridin-3-yl]-3,7-diazabicyclo[3.3.1]nonane
• CAS: 345317-20-6
• 化学式: C₁₃H₁₆F₃N₃
• 分子量: 271.285
• InChiKey: JUHQCXCRXBXFIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Novel heteroaryl-diazabicycloalkanes
  申请人：——

  公开号：US20030004153A1

  公开（公告）日：2003-01-02

  The present invention relates to novel heteroaryl-diazabicycloalkanes which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新型的杂环烷基二氮杂双环戊烷，发现其为烟碱乙酰胆碱受体的胆碱能配体。由于其药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统相关的疾病或紊乱，与平滑肌收缩相关的疾病或紊乱，内分泌疾病或紊乱，神经退行性疾病或紊乱，炎症相关的疾病或紊乱，疼痛以及由于滥用化学物质终止而引起的戒断症状等多种疾病或紊乱具有用处。
• NOVEL HETEROARYL-DIAZABICYCLOALKANES
  申请人：NeuroSearch A/S

  公开号：EP1274710A2

  公开（公告）日：2003-01-15
• US6815438B2
  申请人：——

  公开号：US6815438B2

  公开（公告）日：2004-11-09
• [EN] NOVEL HETEROARYL-DIAZABICYCLOALKANES<br/>[FR] NOUVEAUX HETEROARYLES-DIAZABICYCLOALCANES
  申请人：NEUROSEARCH AS

  公开号：WO2001044243A2

  公开（公告）日：2001-06-21

  The present invention relates to novel heteroaryl-diazabicycloalkanes which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.